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Abstract
Purpose Almost half of people diagnosed with cancer are working age. Survivors have increased risk of unemployment, but little
is known about long-term work retention. This systematic review and meta-analysis assessed work retention and associated
factors in long-term cancer survivors.
Methods We searched Medline/Pubmed, Embase, PsychINFO, and CINAHL for studies published 01/01/2000–08/01/2019
reporting work retention in adult cancer survivors ≥ 2 years post-diagnosis. Survivors had to be in paid work at diagnosis.
Pooled prevalence of long-term work retention was estimated. Factors associated with work retention from multivariate analysis
were synthesized.
Results Twenty-nine articles, reporting 21 studies/datasets including 14,207 cancer survivors, were eligible. Work retention was
assessed 2–14 years post-diagnosis. Fourteen studies were cross-sectional, five were prospective, and two contained both cross-
sectional and prospective elements. No studies were scored as high quality. The pooled estimate of prevalence of long-term work
retention in cancer survivors working at diagnosis was 0.73 (95%CI 0.69–0.77). The proportion working at 2–2.9 years was 0.72;
at 3–3.9 years 0.80; at 4–4.9 years 0.75; at 5–5.9 years 0.74; and 6+ years 0.65. Pooled estimates did not differ by cancer site,
geographical area, or study design. Seven studies assessed prognostic factors for work retention: older age, receiving chemo-
therapy, negative health outcomes, and lack of work adjustments were associated with not working.
Conclusion Almost three-quarters of long-term cancer survivors working at diagnosis retain work.
Implications for Cancer Survivors These findings are pertinent for guidelines on cancer survivorship care. Professionals could
focus support on survivors most likely to have poor long-term work outcomes.
Keywords Cancer . Work retention . Employment . Work ability . Return-to-work . Longitudinal studies . Prospective studies .
Meta-analysis
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Introduction
The sustained improvements in detection and treatment of
many types of cancer have steadily increased life expectancy
after cancer treatment [1]. During the next decade, a further
rapid increase in the number of new cancer diagnoses in the
population and a growing number of cancer survivors are
expected [1].
Almost half of the people diagnosed with cancer are of work-
ing age [2] and it is therefore likely that the prevalence of cancer
survivors in the work force will increase. In addition, the retire-
ment age is rising in many countries, implying that more cancer
survivors will be part of the working population [3].
For both cancer survivors themselves and society, returning
to work is important. Survivors often regard returning to work
as regaining normality and self-respect [4]. It contributes to
their quality of life [5] and provides them with financial secu-
rity [6]. From the viewpoint of the ageing society, it is an
economic and social necessity to encourage survivors to return
to work whenever possible [7].
Cancer survivorship is associated with a range of enduring
physical and psychological effects including long-lasting fa-
tigue [8, 9], depression [9, 10], physical complaints [9, 11],
and neurocognitive limitations [9, 12, 13]. These long-term
outcomes of cancer treatment can have persistent impact on
the work ability of survivors [14]. As a result, cancer survivors
have been shown to have an increased risk of unemployment
compared to the general population in long-term follow-up
studies [15–17].
Several reviews on the impact of cancer treatment on short-
term work outcomes have been published [18–20]. These re-
views showed return to work rates between 39 and 93% with-
in 1–2 years after diagnosis. However, the employment path-
ways of cancer survivors could change after this point because
treatment for cancer can, increasingly, be a long process (tak-
ing a year or more) and survivors can have persistent long-
term effects which may last well beyond 2-year post-diagnosis
[21]. However, the long-term effects of cancer treatment on
work outcomes have not been systematically reviewed. In
addition, the influence of prognostic factors on long-term
work outcomes has not been synthesized.
A systematic review on the long-term work status of cancer
survivors would be of value both for helping shape expecta-
tions of new cancer patients regarding likely long-term out-
comes (including work outcomes), and in psychosocial survi-
vorship care, when counselling survivors on the long-term
psycho-oncological outcomes after treatment [22]. This type
of information can therefore help improve survivors’ quality
of life by preventing work loss and distress.
The aims of the current study are therefore (i) to systemat-
ically assess long-termwork retention among cancer survivors
2 years and more after diagnosis and (ii) to assess associated
factors for work retention in long-term cancer survivors.
Materials and methods
Search strategy
We followed the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines in
conducting this review and preparing the manuscript [23]. We
searched four databases (Medline [Pubmed], Embase,
PsychINFO, CINAHL) to identify studies reporting workforce
retention in long-term cancer survivors, published from 01/01/
2000 to 08/01/2019. We defined long-term survivors as those
who were at least 2 years from diagnosis [24]. Combinations of
disease-related, work-related, and survivor-related search terms
were used (Supplementary Table S1). Disease-related terms
included cancer, neoplasm, carcinoma, tumour, oncology,
radiotherapy and chemotherapy; work-related terms included
employment, unemployment, retirement, sick leave, sickness
absence, absenteeism, presenteeism, work, occupation, work
ability, work disability, disability management, rehabilitation
and vocational; and survivor-related terms included survivor,
survival, and long-term. Wildcards and alternative spellings
were used where appropriate. Only full papers published in
peer-reviewed journals were eligible; we did not include con-
ference abstracts or the gray literature, the former because ab-
stracts rarely contain sufficient detail to be able to determine
eligibility (or appraise quality) and the latter because such stud-
ies are difficult to identify systematically. Reference lists from
reviews of cancer and work identified in the electronic searches
and of eligible papers were scrutinized to identify any poten-
tially eligible articles which might have been missed by the
electronic searches.
Eligibility criteria
To be included, papers had to include survivors who were all
at least 2-years post-diagnosis. If study participants were a
range of times from diagnosis (e.g., 6 months to 3 years), then
the group of long-term survivors (at least 2-years post-diagno-
sis) had to be reported separately. Studies were eligible if they
136 J Cancer Surviv (2020) 14:135–150
included cancers at any site (invasive or in situ) diagnosed in
adults (defined as those aged 18 and older); studies of cancers
diagnosed in children or adolescents were excluded as their
employment outcomes may differ from those of survivors di-
agnosed in adulthood. All survivors in the studies needed to be
employed or in paid work at the time of diagnosis (either for an
employer or self-employed); studies where survivors were in
the labor market at diagnosis but were not all employed/
working (e.g., some were unemployed or job seeking), and
the group employed/working were not reported separately,
were not eligible. In terms of outcomes, studies had to report
a measure of work retention (e.g., percentage employed/unem-
ployed/working or percentage return to work) at 2-years post-
diagnosis and/or later time-points. Our primary interest was in
the proportion of survivors who were working long term; there-
fore, if a study reported survivors by work status category (e.g.,
on sick leave, retired, working) or multiple measures of work
retention, we abstracted the figure for those who were working
(i.e., back in the workplace) at the time the outcome was
assessed. Studies which reported raw figures such as numbers
or percentages of work retention were included and those
reporting only odds ratios or relative risks were excluded.
Quantitative cross-sectional or prospective observational stud-
ies, with or without a control/comparison groups, were eligible,
as were observational studies nested within randomized con-
trolled trials. Trials of vocational or rehabilitation interventions
were excluded as the return to work experiences of participants
may not have been typical of those of the base population. In
addition, we excluded studies of survivors of occupational can-
cers because their return to work experiencesmay not be typical
of all survivors. Only studies where the base population was
knownwere included. To have a reasonable degree of precision
in the estimates of work retention, we excluded studies where
outcome data was available on less than 50 individuals. No
language limits were placed on the search.
Data extraction
Two of the authors independently screened each title and ab-
stract. Full text of papers considered potentially eligible for
inclusion by either or both reviewers were read independently
by the same two reviewers and their suitability for inclusion
assessed. The reviewers then compared results and discussed
any discrepancies; a third author (AdB or LS) was called on in
the event of disagreement. When uncertainty about eligibility
remained, authors of papers were contacted; if they did not
respond after a reasonable time, the paper was excluded.
Data abstraction from eligible papers was done indepen-
dently by two authors. Information extracted on study charac-
teristics included (1) study location (country); (2) study de-
sign; (3) study population including diagnosis, sex, age; (4)
time-points at which outcomes were assessed; and (6) which
outcome(s) were assessed and how. Information was
abstracted on work retention (preferentially percentage work-
ing or returned to work; percentage employed otherwise; per-
centage unemployed was converted into percentage
employed). Information was also abstracted on any risk fac-
tors for work retention (categorized as patient-related, clinical
or work-related) considered. If multivariable analyses of risk
factors were reported, results of these were abstracted and
reported. Finally, details of any other work-related outcomes
reported (e.g., income, working hours) were extracted.
Analysis
Meta-analysis was conducted in Stata 15 [College Station,
Texas, USA], using the metaprop_one command [25], fitting
a logistic-normal random effects model with inverse-variance
weights and the Freeman-Tukey double arcsine transformation.
The pooled proportion working or employed was computed
across all studies. Results for studies which reported the inverse
of the outcome of interest (e.g., unable to work) were subtracted
from 100 before inclusion. In the primary analysis, for studies
which reported multiple time-points, results from the earliest
time-point post-diagnosis were used; a sensitivity analysis
was conducted in which results for the last time-point post-
diagnosis were used instead. Pooled proportions were also
computed for a range of time windows post-diagnosis: 2–
2.9 years, 3–3.9 years, 4–4.9 years, 5–5.9 years, and 6+ years.
In these analyses, studies which reported results at multiple
time-points were included in the analysis for each relevant
time-point. Subgroup analysis was performed for cancer site,
geographical area as defined by the World Health Organization
[26], study design, and sampling frame for the cancer popula-
tion. All tests of statistical significance were two-sided.
Quality appraisal
Full papers of eligible studies were critically appraised, by two
authors (AdB, LS), using the Methodological Index for Non-
Randomised Studies (MINORS) [27]. Where multiple papers
were available from the same study/using the same dataset, we
appraised the paper which included data from a comparative
group or, failing that, the earliest published paper. Studies
were scored on 12 items, eight of which applied to all studies:
the aim of the study, inclusion and retention rate, prospective
data collection, employment endpoints, unbiased assessment
of endpoints, follow-up time after diagnosis, loss to follow-up,
and prospective calculation of sample size. Four additional
items applied only to those studies with control/comparison
groups: comparable control group, contemporary control
group, baseline equivalence of groups, and adequate statistical
analysis. Each study was scored 0/1/2 for each item. Thus, the
total possible score for a non-comparative study was 16 and
for a comparative study was 24. High quality was considered a
score of ≥ 16/24 [2].
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Results
Study selection
Figure 1 shows the number of papers identified, screened, and
included. After removal of duplicates, the initial searches
yielded 5334 records. After screening of titles and abstracts,
229 articles remained. Following full-text review of these, 29
articles were deemed eligible. These final 29 articles reported
findings from 21 different studies or datasets (Table 1)
[28–56].
Study characteristics
Of the 21 studies, six were undertaken in the USA [29, 31, 35,
47, 48, 51], three in the Netherlands [43, 54, 56], two each in
Brazil [39, 55], Canada [36, 40], France [44, 52], and Norway
[33, 38], and one each in Ireland [46], Israel [34], Sweden
[37], and UK [28]. Fourteen studies were cross-sectional
[28, 31, 34, 38, 40, 43, 44, 46–48, 51, 52, 55, 56], five were
prospective [29, 33, 35, 36, 39], and two contained both cross-
sectional and prospective elements [37, 54]. Four studies in-
cluded external comparison groups: one recruited controls
matched to cases [40], two selected comparison populations
from existing panel or labor market surveys [48, 52], and one
used administrative data to identify the population without
cancer [36]. Eleven studies used a population-based cancer
registry [28, 31, 35, 40, 43, 46, 47] or administrative data
[34, 36, 44, 52] as the sampling frame for survivors, with
the other ten studies recruiting from hospital or clinical
sources [29, 33, 37–39, 48, 51, 54–56]. In eight studies, sur-
vivors of a variety of cancers were included [28, 31, 36, 43,
44, 48, 51, 52]; six studies included only breast cancer survi-
vors [29, 34, 35, 37, 39, 40]; three included head and neck
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cancers only (albeit at multiple sites within the head and neck)
[46, 55, 56]; two included colorectal cancers only [47, 54];
one included hematological cancers only [38]; and one includ-
ed prostate cancer only [33].
Sample sizes ranged from 53 to 2597, with 14,207 survi-
vors included in total. The mean age of survivors varied from
42 to 61 years. Work retention was described in terms of
working in 16 studies (“working” in 10 studies [28, 29, 33,
34, 36, 39, 43, 44, 46, 51]; “returned to work” in three [37, 48,
56]; “paid labour resumption” in one [54]; “no longer work-
ing” in one [35]; “unable to work” in one [55]) and in terms of
employment in five studies (“employed” in four studies [31,
38, 47, 52]; and “unemployed” in one [40]).
Work outcomes were assessed by self-report in 20 studies
and from administrative data in one study [36]. The time at
which work retention was assessed ranged from 2 to 14 years
post-diagnosis. Five studies (one prospective [29], three cross-
sectional [46, 48, 52], and one mixed [37]) reported work
retention at multiple time points.
Quality assessment
Of the non-comparative studies, for which the maximum pos-
sible score was 16, ten scored ≤ 8 [28, 34, 38, 43, 44, 46, 47,
51, 55, 56] and seven scored 9 or more [29, 31, 33, 35, 37, 39,
54] (Supplementary Table S2). The four studies with a com-
parison population scored in the range 12–15 out of a maxi-
mum score of 24 [36, 40, 48, 52]. As a result, no studies
scored as high quality mainly due to lack of non-cancer con-
trol groups. Across studies, the areas where studies scored
poorly were lack of prospective data collection, unclear end-
points, failure to report a priori sample size calculation, and
failure to report loss to follow-up.
Workforce retention among long-term survivors
The pooled estimate of the proportion of survivors working at
≥ 2 years post-diagnosis was 0.73 (95%CI 0.69–0.77) (Fig. 2).
Heterogeneity was significant (I2 = 96.4%). In the sensitivity
analysis, in which the final (rather than earliest) time-point
was included for the five studies which reported work reten-
tion at multiple time-points [30, 37, 46, 48, 52], the pooled
estimate was 0.75 (95%CI 0.70–0.79, I2 = 96.0%).
The proportion working at different time-points after diag-
nosis was as follows: 2–2.9 years (reported in seven studies):
0.72 (95%CI 0.66–0.77); 3–3.9 years (8 studies): 0.80
(95%CI 0.74–0.86); 4–4.9 years (4 studies): 0.75 (95%CI
0.67–0.83); 5–5.9 years (4 studies): 0.74 (95%CI 0.66–
0.81); 6+ years (5 studies): 0.65 (95%CI 0.60–0.69).
Figure 2 shows that there was no significant difference in
the pooled estimate between subgroups defined by cancer site
(mixed sites: 0.76 (95%CI 0.69–0.82); breast: 0.70 (95%CI
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colorectal: 0.71 (95%CI 0.66–0.75); and other individual
sites: 0.75 (95%CI 0.71–0.79); subgroup heterogeneity
Chi-square = 4.34, 4 df, P = 0.36). By geographical area
(Fig. 3), the pooled estimates were Europe 0.74 (95%CI
0.69–0.79), North America 0.75 (95%CI 0.68–0.81), and
elsewhere 0.66 (95%CI 0.62–0.70). There was no dif-
ference in the pooled estimate by study design (cross-
sectional: 0.72 (95%CI 0.68–0.76); prospective: 0.75
(95%CI 0.65–0.84); subgroup heterogeneity Chi-
square = 0.37, 1 df, P = 0.54) or data source (popula-
tion-based/administrative: 0.72 (95%CI 0.67–0.77); clin-
ical: 0.74 (95%CI 0.66–0.82); subgroup heterogeneity
Chi-square = 0.21, 1 df, P = 0.65) (Supplementary
Figures S1 and S2).
Studies with non-cancer comparators
The five articles describing the four studies which included
comparison groups reported lower long-term work retention
among survivors than comparators [36, 40, 49, 50, 52]. In
Canada, Maunsell et al. found that the relative risk of unem-
ployment at 3 years was significantly higher among survivors
(RR = 1.29, 95%CI 1.05–1.59) [40]. Also, in Canada, Jeon
et al. reported that 85% of survivors were working at 25–47-
Heterogeneity between groups: p = 0.361
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Fig. 2 Proportion of survivors who have returned to work 2+ years post-diagnosis by cancer site
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month post-diagnosis compared to 94% of comparators [36]. In
France, compared to matched comparators, the percentage of
survivors who were employed at 2-years post-diagnosis was
lower among both salaried (79% vs 94%) and self-employed
(86% vs 96%) individuals [52]. In the USA, the employment
rate at 2–6-years post-diagnosis was 7–8% lower for survivors
aged 25–54 than age-matched comparators [50] and 4% lower
for survivors aged 55–65 than similarly aged comparators [49].
Risk factors for work retention among long-term
survivors
Seven studies investigated patient-related, clinical, and/or
work-related risk factors for work retention among long-
term cancer survivors and analyzed them in a multivariate
analysis [28, 29, 35, 39, 40, 52, 55] (Table 2).
Of the patient-related factors, older age [35, 40, 52]
and lower income at diagnosis [39, 40, 52] were signif-
icantly associated with not returning to work in multi-
variate analyses in three studies. The clinical factors
receiving chemotherapy [35, 52], having comorbidities
[30, 35, 52], having a new cancer event [40, 52], hav-
ing a poor prognosis [52, 55] or depression [39, 52],
and the work-related factor lack of work adjustments
[35, 39] were associated in multivariate analyses with
not returning to work.
Other work-related outcomes
Sixteen studies reported other work-related outcomes among
survivors (Table 3). Of the nine studies which examined chang-
es in working hours among survivors [28, 33, 34, 39, 40, 43,
46, 48, 52], six studies reported that 12–52% of survivors who
Heterogeneity between groups: p = 0.014
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had returned to work had reduced their working hours com-
pared to before diagnosis [28, 39, 40, 43, 46, 52]. One study
reported that survivors worked fewer hours than similarly aged
people without cancer [48]. In three studies, the proportion of
survivors working part-time had increased and/or the propor-
tion working full-time had decreased [33, 34, 40].
Five studies reported on other changes in survivors’ work
situations. There was no difference in the proportion of breast
cancer survivors (19%) who had changed job at 3 years
compared to non-cancer comparators [40]. Another study of
a mixed group of survivors reported that 8% had changed
employer at 3 years [28]. Three studies reported that a propor-
tion of survivors (13–55%) had had to reduce workload,
change their working schedule, or make adaptations due to
cancer [31, 38, 56].
Three studies described income post-diagnosis [36, 39, 40].
In one, during 25–47-month post-diagnosis, survivors earned
9% less than comparators [36] and, in another, 21% of
Table 2 Risk factors for work retention among longer-term cancer survivors
Author and year Risk factors assessed Resultsa
Amir et al., 2007 [28] • Patient-related: gender, deprivation
• Clinical: surgery
• Work-related: length of sick leave
Longer sick leave (OR = 1.68, 1.2–2.3) and absence
of surgery (OR = 0.28, 0.08–0.9) were significantly
associated with working 3 years after diagnosis
Blinder et al., 2012 [29];
Blinder et al., 2013 [30]
• Patient-related: age, race/ethnicity, birthplace,
household income, adequate financial resources,
marital status, children living at home, seniors living
at home, education, acculturation, social support
• Clinical: comorbid conditions, stage at diagnosis, type
of surgery, breast reconstruction, axilliary node
dissection, chemotherapy, radiotherapy, endocrine
therapy
• Work-related: job type, full/part-time work at diagnosis
Presence of comorbid conditions (OR = 0.25, 0.08–0.7)
was significantly associated with not returning to
work 3–5 years postdiagnosis
Jagsi et al., 2014 [35] • Patient-related: age, race, education, family income,
marital status, area of residence, family income
• Clinical: comorbidities, stage at diagnosis, type of
surgery, chemotherapy, radiotherapy
• Work-related: full/part time work at diagnosis,
employment support (sick leave/flexible schedule)
Older age at diagnosis (≥ 56 vs < 46: OR = 1.42, 1.03–1.9),
receipt of chemotherapy (OR = 1.42, 1.03–1.98),
comorbidities (≥ 2 vs none: OR = 2.16, 1.6–2.9), and
lack of work adjustments (none vs sick leave and/or flexible




• Patient-related: education, age, changes in marital status,
• Clinical: health status, weight gain, depression, pain,
lymphedema, breast conserving surgery, breast
reconstruction, axillary dissection, chemotherapy,
radiotherapy, endocrine therapy, anti-HER2 therapy,
quality of life
• Work-related: changes in income, work adjustment,
employer discrimination, employer support
Higher household income (OR = 16.6, 1.8–155), work adjustments
(OR 37.6, 3.31–427), breast conserving surgery (OR 9.8,
2.0–47), not having depression (OR 14.3, 1.6–100), and not
having endocrine therapy (OR 9.1, 1.3–50) were significantly
associated with working at 2 years post-diagnosis
Maunsell et al., 2004 [40];
Drolet et al., 2005a [41];
Drolet et al., 2005b [42]
• Patient-related: age, living with partner, children,
education, personal income
• Clinical: disease status since diagnosis (disease-free
vs recurrence/contralateral breast cancer);
radiotherapy, chemotherapy, hormone therapy,
affected nodes
• Work-related: union member, experience in job,
type of job, hours per week, value of work
Significant predictors of not working at 3 years were: older
age (50–59 vs 18–39 OR = 4.62, 2.2–9.5), lower personal income
(< $20,000 vs ≥ $50,000 OR = 3.18, 1.6–6.3), new cancer event
(OR = 2.14, 1.5–3.1), union membership (union membership
yes vs no OR = 1.88, 1.3–2.7; self-employed vs not union
member OR = 0.60, 0.3–1.05), and value of work since
diagnosis (decreased vs increased: OR = 1.83, 1.1–3.0)
Tison et al., 2016 [52];
Alleaume et al. 2018 [53]
• Patient-related: marital status, gender, age,
dependent children
• Clinical: cancer prognosis, adverse cancer event,
chemotherapy, radiotherapy, comorbidities, mental
health, chronic neuropathic pain
• Work-related: employment sector at diagnosis,
socio-professional status, wages at diagnosis,
full-time/part-time at diagnosis, type of employment
contract, self-employed versus employee, business sector
Older age, not having children, and poor cancer prognosis, were
significantly related to not working at 2 years after cancer diagnosis.
Age 18–39 (OR 1.69, 1.00–2.9) or age 50–54 (OR 1.65, 1.06–2.6),
not having children (OR 2.1, 1.3–3.4), poor cancer prognosis
(OR 3.6, 1.6–8.2), adverse cancer event (OR 2.1, 1.3–3.3),
chemotherapy (OR1.6, 1.1–2.4), comorbidities (OR 2.0,
1.2–3.4), mental health (OR 0.96, 0.95–0.98), chronic
neuropathic pain (OR 2.6, 1.7–3.9), private sector (OR 2.5,
1.5–4.3), execution function (OR 2.2, 1.4–3.2), and higher
wages at diagnosis (OR 1.01, 0.99–1.03) were significantly
related to leaving employment at 5 years after cancer diagnosis
Vartanian et al.
2006 [55]
• Patient-related: gender, age, alcohol use, education,
pain, quality-of-life score
• Clinical: cancer site, stage, treatment,
permanent tracheostomy
More advance stage (VI vs I OR = 3.5, 1.5–8.1), alcohol use before
treatment (OR = 2.6, 1.3–5.2), and lower education (high school
or college vs illiterate OR = 0.2, 0.5–0.8) were significantly
associated with being unable to work > 2 years post-diagnosis
a Only results significant in multivariable analyses are reported
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Table 3 Other work-related outcomes among longer-term cancer survivors
Author and year Work-related outcomes
assessed
Results
Amir et al., 2007 [28] • Change in working hours
• Change in place of work
• Perception of work
• 18% of survivors who took < 6 months sick leave, and 43% of those who took ≥
18 months sick leave, changed their working hours compared to before diagnosis
• 8% of survivors who had returned to work changed to a different place of work
• 19% of survivors who returned to work reported that their overall working life
had deteriorated due to cancer
Bradley and Bednarek, 2002 [31];
Bednarek and Bradley, 2005 [32]
• Change in work schedule • 54% of survivors reduced their workload/working schedule at least once
because of cancer
Dahl et al., 2015 [33] • Reduced working hours
• Influence of prostate
cancer on working life
• 66% of survivors worked full-time at 3 years compared to 75% at diagnosis
• 34% of survivors reported that prostate cancer had influence their working life
to some/great extent. In multivariable analysis among men active in the
workforce, adjuvant/salvage treatment, chronic fatigue, physical work and bother
with urinary leakage were significantly associated with believing prostate cancer had
influenced working life to some/great extent.
Hamood et al., 2018 [34] • Change in working hours • At a mean of 8.5 years post-diagnosis, 48% of survivors had changed from full-time
to part-time employment. In multivariate analyses, immigration status (country of birth
not Israel) was significantly associated with changing from full-time to
part-time employment
Jagsi et al., 2014 [35] • Seeking work • At 4 years post-diagnosis, 39% of survivors who were not employed were actively
looking for work
Jeon, 2016 [36] • Income • During 25–47 months post-diagnosis, survivors earned 9.0% less than comparators.
The difference was greatest for those with cancers of low survival.
Kiserud et al., 2016 [38] • Work changes
due to cancer
• Work ability
• 13% of survivors who returned to work reported work changes due to cancer
• Work ability was higher among those working at survey than not working
(mean = 7.3 vs 3.6); 11% of those working vs 59% of those not working had
poor physical work ability; 6% of those working vs 33% of those not working
had poor mental work ability; change in work ability was lower among those
working than those not working




• Among survivors who returned to work, 12% decreased and 3% increased
working hours
• 21% reported a reduction in monthly income
• 11% reported perceived employer discrimination
Maunsell et al., 2004 [40];
Drolet et al., 2005a [41];
Drolet et al., 2005b [42]
• Change in working hours
• Change in job
• Income
• Sickness absence
• Among survivors employed at 3 years, hours worked per week in main/only and
any second job were significantly lower than at diagnosis
• 19% of survivors (20% of those disease-free and 13% of those not disease-free)
vs 20% of comparators were employed in a different job than at diagnosis
• At 3 years, the increase in the proportion who earned $30,000+ per annum
(compared to at diagnosis) was similar in survivors and comparators
• In the third year from diagnosis, 23% of survivors were absent from work for ≥ 4
weeks vs 19% of comparators. Average duration of absence was longer in
survivors who were not disease free, compared to those who were disease
free (4.1 weeks vs 2.1 weeks).
Mols et al., 2009 [43] • Change in working hours • At survey, 17% of survivors worked fewer hours than at diagnosis
Paraponaris et al., 2010 [44];
Marino et al., 2013 [45]
• Sickness absence • 20% of survivors who were employed at diagnosis and at 2 years took no sick leave
Pearce et al., 2013 [46] • Change in working hours • Among survivors who returned to work, 52% reduced and 3% increased
working hours compared to at diagnosis
Sanchez et al., 2004 [47] • Sickness absence • Of survivors who resumed working, 36% returned after ≥ 60 days absence. In
multivariate analyses, receipt of chemotherapy was significantly related to
returning after 60 days
Short et al., 2005 [48]; Farley
Short et al., 2008 [49];
Moran et al., 2011 [50]
• Hours worked • At 2–6 years post-diagnosis, female survivors aged 28–54 worked 3–4 hours less
per week than similarly-aged females in comparison population; male
survivors aged 28–54 worked 5–6 hours less than similarly-aged males in comparison
population. Female survivors aged 55–65 worked 3–4 hours less per week than
similarly-aged females in comparison population; male survivors aged
55–65 worked 3.5–5 hours less than similarly-aged males in comparison population
Tison et al., 2016 [52];
Alleaume et al., 2018 [53]
• Change in working hours • Of survivors who had returned to work at 5 years, 32% had reduced working hours
compared to diagnosis. In multivariate analysis, wages at diagnosis, sector of
employment at diagnosis, chemotherapy, mental health score and chronic neuropathic
pain were significantly associated with reduced working hours at 5 years
Verdonck-de Leeuw
et al., 2010 [56]
• Change in work • Of survivors who resumed working, 36% had changed work (i.e. returned to adapted
work or to other work).
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survivors reported reduced monthly income [39]. In contrast,
at 3 years, the increase in the proportion who earned
≥ $30,000 per annum (compared to at diagnosis) was similar
in survivors and comparators [40].
Discussion
Summary of main findings
This systematic review indicates that 73% of long-term cancer
survivors who were working at diagnosis return to work and
that long-term survivors are less likely to be working than
people without cancer. However, there is significant heteroge-
neity in estimates of work retention between studies.
Prognostic factors for not returning to work among long-
term survivors include older age, lower income at diagnosis,
comorbidities, receipt of chemotherapy, and lack of work ad-
justments, but these have been investigated in relatively few
studies. In terms of other outcomes, a proportion of long-term
survivors reduce their working hours compared to at diagno-
sis, and somemake other work-related changes; theymay also
have reductions in income. However, these outcomes have
been reported in few studies.
Interpretation of results
Our pooled estimate of the prevalence of work retention in
long-term survivors is slightly higher than estimates of return
to work from previous reviews which largely included studies
of shorter-term survivors (Spelten et al., 62% [18]; Mehnert,
64% [19]). For the current review, only studies in which all
survivors were working at diagnosis were eligible for inclu-
sion; this was not a requirement in previous reviews and could
explain the apparently higher rate of work resumption ob-
served here (since not working at diagnosis is a predictor of
not working after cancer [44, 57]). Although some studies
suggest that a longer period of work absence after a cancer
diagnosis is associated with reduced likelihood of work re-
sumption [28, 45], there is also evidence that rates of sickness
absence post-cancer decrease over time and a proportion of
those who are absent long-term eventually return to work [46,
58]. Thus, the higher rate of return to work in long-term sur-
vivor may be real.
To shed further light on this, we sought to investigate the
temporal trajectory of work retention in long-term survivors.
However, only five studies reported work resumption at more
than one time-point (and three of these had a cross-sectional
design) [29, 37, 46, 48, 52], and information onwork retention
at 6 or more years post-diagnosis was only available from five
studies which reported outcomes at a heterogeneous range of
follow-up times (e.g., 5–7 years, 12 years, > 2 years) [31, 34,
38, 43, 55]. Nonetheless, the meta-analysis suggested that
there may be a modest trend in work retention—higher in
years 3–3.9 than years 2–2.9 followed by a modest decline
in later periods. This later decline is consistent with a recent
Japanese study which showed that, among male cancer survi-
vors, the rate of work continuation after return to work de-
creased steadily over time and that, on average, survivors con-
tinued working for only 4.5 years after work resumption [59].
The decline in work participation over time could reflect
people dropping out of the workforce due to diagnosis of
a second primary cancer or other cancer-related symptoms
or late effects. Survivors who have returned to work can ex-
perience a range of physical or psychological after-effects
which adversely impact their work ability or functioning
[60, 61]. In addition, cancer-related symptoms, such as fa-
tigue, pain, and depression, have been associated with leaving
the workforce after cancer, albeit mainly in shorter-term sur-
vivors [62–64]. Alternatively, the decline may simply reflect
ageing and people reaching retirement age or opting for early
retirement. While a significant proportion of cancer survivors
want to retire early [65], and there is an excess risk of early
retirement among survivors [66], some of those who do retire
feel that they were forced into this rather than it being a free
choice [32]. Further research is needed to clarify long-term
temporal trajectories of work retention (and related outcomes,
such as early retirement) among cancer survivors, and the
factors influencing survivors’ decisions to leave the workforce
after initially resuming work.
We found a suggestion of geographical variation in work
retention after cancer, with a lower prevalence in studies
conducted outside North America and Europe. However,
there was significant within-group heterogeneity so it is
likely that the P value from the test of between-group het-
erogeneity is too small [67]. Moreover, only three studies
were included from outside Europe and North America, two
from Brazil and one from Israel, and the largest of these
included only 301 survivors [34, 39, 55]. Our rationale for
grouping countries was that there is legislation intended to
protect cancer survivors against discrimination at work in
place in much of Europe [68] and North America (e.g.,
Americans with Disabilities Act [69]), but this may not be
the situation elsewhere. Given this, it was striking that we
found almost identical prevalence of work resumption in the
studies from Europe and North America. This is consistent
with conclusions from a 2009 meta-analysis of risk of un-
employment in cancer survivors which reported no signifi-
cant difference between Europe and the USA once cancer
site, age, and background employment rate had been
accounted for [2]. However, it is worth noting that the prev-
alences reported here from the European and North
American studies varied widely (Europe: range 56% [38]
to 93% [33]; North America: 56% [29] to 85% [36]). This
indicates the need for further large-scale studies of long-
term survivors in all settings.
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The prognostic factors for work retention among long-term
survivors identified here are broadly consistent with those report-
ed in reviews which have mainly considered short-term work
outcomes [18, 19, 70]. For example, in reviews of prognostic
factors for return to work following breast or colorectal cancer,
older age, receipt of chemotherapy, and presence of comorbidi-
ties were identified as inhibiting factors [71, 72], which we also
found. Several other prognostic factors identified here—such as
lack of work adjustments, self-employment, perceived value of
work, and not having children—were seen in single studies and
require confirmation.
Strengths and limitations
This is the first review to focus on long-term survivors, a
group of growing size. We followed systematic review guide-
lines in conduct and reporting (PRISMA) [23] and used a
valid and reliable tool to assess quality (MINORS) [27]. We
minimized the possibility of missing relevant articles by
searching multiple databases using terms designed to be sen-
sitive and by reviewing reference lists of included papers and
other reviews. To maximize comparability of estimates of
prevalence of work retention across studies, we considered
studies eligible only if all survivors were in paid work at the
time of diagnosis. Despite this, there was heterogeneity in the
estimates of work retention observed and it is likely that this
was driven by the heterogeneity in study design and conduct.
For example, authors used different terms for work retention
(e.g., working, employed) but failed to define precisely what
these meant (e.g., whether the “employed” group included
people who were still on sick leave); most failed to state
whether both full and part-time work was considered as work-
ing post-diagnosis; and most did not indicate whether they
excluded some groups of survivors from follow-up (e.g., those
with recurrent disease). All of these issues could have a sig-
nificant impact on the estimate of work retention.
In addition, the quality appraisal indicated that none of the
studies would be considered high quality. It is well recognized
that studies ofworkforce participation after cancer should include
non-cancer comparators to allow for the effect of cancer onwork-
force participation and general labor market trends to be distin-
guished [73]. Despite this, surprisingly, few studies (only 4) in-
cluded non-cancer comparators. This contrasts with the 2009
systematic review of unemployment in cancer survivors which
included 26 studies, all ofwhich had non-cancer comparators [2].
Studies in the current review scored poorly in terms of lack of
prospective design, failure to report a priori sample size calcula-
tions and failure to report loss to follow-up. In addition, work
retention was self-reported in 20 of the 21 studies, using a variety
of data collection methods and instruments/questions; none of
these instruments/questions appeared to have been rigorously
validated.Most studies were small—only six includedmore than
500 survivors [35, 36, 40, 44, 48, 52]. Eight included a mixed
group of cancer survivors (and insufficient numbers to allow site-
specific analyses) [28, 31, 36, 43, 44, 46, 48, 51, 52], even
though cancer site is likely to be a significant prognostic factor
for work-related outcomes [59, 70].
Considering the evidence-base as a whole, this review in-
dicates that important gaps remain around work retention in
long-term cancer survivors. Little is known about patterns and
predictors of long-term work retention in most countries be-
yond North America and selected European populations.
System-level factors (e.g., social welfare provisions, insur-
ance, legal provisions) are likely to be important influences
on work outcomes among cancer survivors [74], but have not
been investigated as influences among long-term survivors.
Little is known about most cancers, other than breast (most
of the studies of mixed cancer sites were dominated by breast
cancer). Little is known about how work retention—and other
work-related outcomes (such as income)—evolve over time in
long-term survivors.
Future directions: Research
High-quality, population-based, longitudinal studies, which
include non-cancer comparators, are needed to fill the evi-
dence gaps identified by this review and clarify the work re-
tention trajectory in long-term cancer survivors. While studies
involving primary data collection would be useful (as they
allow collection of detailed data about work outcomes and
prognostic factors), studies which involve linkage of adminis-
trative and health datasets would also be of considerable value
(see, for example, Grinshpun [57], Jeon [36], Heinesen [75]).
This review also indicates a clear need for harmonization of
data and methods across the research community. In particu-
lar, there is an urgent need to develop standard instruments to
assess work retention (and other work-related outcomes)
which could be used internationally. The European
CANWON network [76] has embarked on a consensus pro-
cess to develop such a tool. Initiatives to pool patient-level
data from studies in different settings could also be of value
in understanding system-level drivers.
Future directions: Practice
The findings of this review—particularly regarding the pro-
portion of survivors who retain work long-term—are relevant
for patients and patient advocacy groups, and for cancer cli-
nicians, oncology nurses, general physicians, and occupation-
al health care professionals who counsel and advise cancer
patients. Professionals may also consider focussing support
efforts on those subgroups of survivors most likely to have
poor long-term work retention outcomes. The findings are
also pertinent for the development and update of oncological
guidelines on cancer survivorship care.
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Conclusions
This systematic review indicates that 73% of long-term cancer
survivors who were working at diagnosis return to work, and
that long-term survivors are less likely to be working than
people without cancer. Prognostic factors for not returning to
work among long-term survivors include older age, lower
income at diagnosis, comorbidities, and receipt of chemother-
apy, but these have been investigated in relatively few studies.
High-quality, population-based, longitudinal studies, which
include non-cancer comparators, are needed to fill the evi-
dence gaps identified by this review and clarify the work re-
tention trajectory in long-term cancer survivors.
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